Biomerieux Sa · EURONEXT:BIM
Biomerieux Sa — FY2024 Earnings Presentation
26 slides from Biomerieux Sa's earnings presentation, Mar 7, 2025
Slide 1: Pioneering Diagnostics - FY 2024 Results
CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER March 7th, 2025 PIONEERING DIAGNOSTICS
Slide 2: Forward-looking statements disclaimer
This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further
Slide 3: Pioneering Diagnostics
PIONEERING DIAGNOSTICS
Slide 4: 2024: a strong start towards GO.28 ambitions
2024: a strong start towards GO•28 ambitions 2024 SALES GROWTH +7% sales growth CAGR at CER1 over 2024/2028 +10.3%1 vs 2023 +340 bps cEBIT2 margin 2024 CEBIT 2 expansion in 2028 at CER1 vs 2023 +150 bps margin at CER1 At least 10% cEBIT2annual organic growth at CER1 +20% cEBIT2 at CER1 1st quartile
Slide 5: FY 2024 Key highlights
FY 2024 Key highlights CONTRIBUTIVE FREE SALES EBIT CASHFLOW +10.3%1 16.9% Net Debt / EBITDA of sales X 0.04 Strong sales dynamic driven by the GO.28 four growth engines (BIOFIRE® non-Respiratory Panels, SPOTFIRE®, Microbiology and Industrial Applications) up +13.4% +20% organic CEBIT growth1, w
Slide 6: BIOFIRE non-respiratory panels: on-going expansion
Growth Driver #1 BIOFIRE® non-respiratory panels: on-going expansion Successful cross selling strategy • 78% of customers using at least 2 panels (up +3 pp vs Dec. 2023) • 52% of customers using at least 3 panels (up +4 pp vs Dec 2023) GO.28 target: +10%** Installed Base / Customer expansion: •
Slide 7: SPOTFIRE exceeding 2024 sales guidance
Growth Driver #2 SPOTFIRE® exceeding 2024 sales guidance Best in class solution for the Point of Care market • Fast: 15 minutes Time To Result • Easy to use: CLIA Waived • Most comprehensive Respiratory menu • Respiratory: 5-plex & 15-plex 2028 target: €450m • Respiratory Sore Throat (incl. Strep
Slide 8: Microbiology: strong reagents sales performance
Growth Driver #3 MICROBIOLOGY: strong reagents sales performance Building on our leadership position • BACT/ALERT® & VITEK® reagents: +13% sales growth GO.28 target: +6/8%** • Volumes expansion and price increases (+4pp on reagents) Strong commitment to innovation • Large adoption of VITEK® MS P
Slide 9: Industrial Applications: growing in line with GO.28 expectations
Growth Driver #4 INDUSTRIAL APPLICATIONS: growing in line with GO.28 expectations GO.28 target: +7/9%** Balanced growth between food and healthcare segments • Reagents sales up > 12% • Price increases : > +6% Leveraging on innovation • Food S&Q molecular segment sales up +30% with strong GENE-UP
Slide 10: Maximizing value of installed base for BIOFIRE respiratory panels and Immunoassays
Maximizing the value of the existing installed base for BIOFIRE® respiratory panels and Immunoassays Leveraging the BIOFIRE® installed base BIOFIRE GO.28 target: flat** Double-digit sales growth driven by sustained Respiratory Panels epidemiology FY24 Sales: Limited price erosion (<1%) €839m**
Slide 11: GO Simple is well on track
GO Simple is well on track SELECTED EXAMPLES COGS EFFICIENCY & IMPROVEMENTS SIMPLICITY SUPPORT FUNCTIONS of BIOFIRE OPTIMIZATION pouches with fully Headcounts automated in 2024 vs 2023 manufacturing in H2 24 IS nearshoring B I O M É R I E U X
Slide 12: 2024: Multiple new product launches
2024: MULTIPLE NEW PRODUCT LAUNCHES BIOFIRE® BIOFIRE®1 Tropical Fever Gastrointestinal Panel Mid (11-Plex) SPOTFIRE® GENE-UP® TYPER Respiratory / Sore Throat (R/ST) Root cause analysis 15- Plex Panel Trusted Third Party SPOTFIRE® Data solution for supply risk Respiratory / Sore Throat (R/ST) 5-Plex
Slide 13: CSR: significant progresses over 2024
CSR: significant progresses over 2024 All data as of December 2024 PLANET EMPLOYEES HEALTHCARE EXTENDED HEALTH ECOSYSTEM COMPANY +19% Collaboration projects 1.7% -13% Lost Day Incident Rate with patient associations of net income Group share patient results vs 2019 vs. 2021 GHG absolute emissions 1.
Slide 14: Financial Performance
Financial Performance PIONEERING DIAGNOSTICS
Slide 15: 2024 Sales: +10.3% driven by GO.28 growth drivers
2024 Sales: a dynamic +10.3%* driven by GO.28 growth drivers SPOTFIRE €95m 3,000 instruments installed at the end of Dec. 2024 MICROBIOLOGY +8% Available in 24 countries. Very strong performance led by automated ID/AST and Blood Culture reagents BIOFIRE® Instr. & Services Flat Volumes and pr
Slide 16: FY 2024 sales by geography
FY 2024 sales by geography EMEA +7%* NORAM +11%* €1,269m 32% of sales €1,793m BIOFIRE® sales up 45% of sales > 20% & Industrial Solid sales growth Applications sales in BIOFIRE® and up +8% Industrial Applications ASPAC +5%* LATAM €656m +33%* 16% of sales €262m Clinical sales up double digit in ASEAN
Slide 17: FY 2024 P&L: CEBIT up +20% like-for-like
FY 2024 P&L: CEBIT up +20% like-for-like1, margin improvement FY % FY % % % In €m Change LFL(1) 2024 sales 2023 sales Change Net sales 3,980 3,675 + 8.3% + 10.3% Gross profit 2,215 55.7% 2,057 56.0% + 7.7% + 11.6% SG&A -1,099 -27,6% -1,021 -27.8% +7.6% + 9.5% R&D -491 - 12.3% -460 -12.5% + 6.8% + 7.
Slide 18: FX: a reduced headwind in 2025
FX : A REDUCED HEADWIND IN 2025 2024 currency effect on CEBIT FX exposure on Estimated impact of +/- 5% FX revenues variation vs EUR on contributive (2024 basis) operating income (1) USD & related(2) 46% +/- € 12m Chinese Yuan 6% +/- € 6m Indian Rupie 3% +/- € 5m 2025 expected currency effect on Pou
Slide 19: FY 2024 P&L: significant increase in EPS
FY 2024 P&L: significant increase in EPS FY % FY % % change In €m 2024 sales 2023 sales as reported CEBIT 673 16.9% 610 16.6% +10.4% Amortization of acquired intangible assets & related expenses -58 -171 Other non-recurring income (expenses) -26 0 Operating income 589 14.8% 439 11.9% +34.1% Net fina
Slide 20: Strong cash flow generation
STRONG CASH FLOW GENERATION • Inventories (-€85m) driven by inventory build- up for new instruments launches and to support the steady demand in BIOFIRE® reagents Millions € December 2024 December 2023 • Receivables (-54m): in line with the increase in business activity EBITDA (1) 914 827 • Other WC
Slide 21: Acquisition
Acquisition PIONEERING DIAGNOSTICS
Slide 22: Integration of SpinChip - Immunoassay POC
Integration of SpinChip - Immunoassay POC 2012 – Establisment by Stig Morten BORCH 2022 - Verification through APACE study 2024 - bioMérieux acquires 20% minority stake Based in Oslo 2025 - bioMérieux acquires 100% ~60 employees Capillary blood (14µL) Easy to use Sealed test cartridge Embedded self-
Slide 23: Strategy and Financials
Strategy and Financials • Strengthen bioMérieux positioning in the promising Point of Care segment • Flexible solution that will first address acute near-patient-testing in the hospital Ambitions • Pre-revenues company: paves the way to future growth. Revenues expected to become significant post 202
Slide 24: 2025 Outlook
2025 outlook PIONEERING DIAGNOSTICS
Slide 25: 2025 Outlook fully aligned with GO.28 ambitions
2025 Outlook fully aligned with GO.28 ambitions Non-RP > 10%, Microbiology ~+7%, Industrial Applications ~+8%, Immuno~0%, Spotfire: ~€190m SALES Organic Respiratory panels: ~ flat assuming a medium flu season at the GO.28 ambition: 7% CAGR (24-28) at CER1 end of 2025 Combination of sales growt
Slide 26: bioMérieux - Pioneering Diagnostics
BIOMERIEUX PIONEERING DIAGNOSTICS